Tifeglipron clinical trials
Also written RO7795081 and CT-996.
How each study uses Tifeglipron is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Tifeglipron studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2025 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test Tifeglipron.
- Dec 2026A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult ParticipantsPhase 1 · Hoffmann-La Roche
- Jan 2027A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or OverweightPhase 1 · Hoffmann-La Roche
Studies
Open first, then newest update. How each study uses Tifeglipron is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 DiabetesRecruitingPhase 2Hoffmann-La RocheNCT07112872Written as Tifeglipron
- A Study Investigating the Safety of RO7795081 and How the Body Processes RO7795081 in People With Normal or Decreased Kidney FunctionsRecruitingPhase 1Hoffmann-La RocheNCT07741604Written as RO7795081
- A Study Evaluating the Effect of Daily Oral Tifeglipron (RO7795081) in Participants With Obesity or Overweight With at Least One Weight-Related ComorbidityCompletedPhase 2Hoffmann-La RocheNCT07081958Written as Tifeglipron
- A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or OverweightActive, not recruitingPhase 1Hoffmann-La RocheNCT07499050Written as RO7795081
- A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult ParticipantsActive, not recruitingPhase 1Hoffmann-La RocheNCT06982131Written as RO7795081
- Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes MellitusCompletedPhase 1Carmot Australia First Pty LtdNCT05814107Written as CT-996
Given beside what is tested · 1 — Tifeglipron is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 18, 2026.